579 results on '"Buse, J."'
Search Results
2. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
3. Proportion of patients with systemic inflammation and their characteristics for groups at high cardiovascular risk in phase 3 randomized placebo-controlled trials of semaglutide (SELECT, SOUL, FLOW)
4. Clinical implications for biochemical diagnostic thresholds of adrenal sufficiency using a highly specific cortisol immunoassay
5. Factitious ACTH‐dependent, apparent hypercortisolism: The problem with late‐night salivary cortisol measurements collected at home
6. Novel measures of inflammation and insulin resistance are related to obesity and fitness in a diverse sample of 11–14 year olds: The HEALTHY Study
7. Current transformer saturation compensation based on a partial nonlinear model
8. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
9. An Endangered Longhorn Beetle Associated with Old Oaks and Its Possible Role as an Ecosystem Engineer
10. Spannende Insektenvielfalt im Totholz
11. Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
12. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial
13. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations
14. Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials
15. Is insulin the most effective injectable antihyperglycaemic therapy?
16. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study
17. Exposure to arsenic and cardiometabolic risk in Chihuahua, Mexico
18. The Structure of the Rarotongan Verbal Piece
19. The Structure of Rarotongan Nominal, Negative, and Conjunctival Pieces
20. Two Samoan Ceremonial Speeches
21. Rarotongan Sentence Structures
22. Rarotongan Personal Pronouns: Form and Distribution
23. Temperature drives variation in flying insect biomass across a German malaise trap network
24. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
25. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience
26. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes
27. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy
28. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
29. Efficacy of oral semaglutide according to diabetes duration: An exploratory subgroup analysis of the PIONEER trial programme
30. Erratum: 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). (Diabetes Care, (2020) 43, (487-493), 10.2337/dci19-0066)
31. Evidence for gene-smoking interactions for hearing loss and deafness in Japanese American families
32. Correction to: 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD) (Diabetologia, (2020), 63, 2, (221-228), 10.1007/s00125-019-05039-w)
33. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
34. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
35. The metabolic syndrome: time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes
36. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial
37. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme
38. Cardiovascular safety of liraglutide: a pooled analysis from phase II and III liraglutide clinical development studies: O6
39. Cardiovascular risk factors in multi-ethnic middle school students: the HEALTHY primary prevention trial
40. Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study
41. ACHIEVING THE COMPOSITE ENDPOINT ‘HBA1c < 7.0%, NO WEIGHT GAIN, NO HYPOGLYCAEMIA’ WITH LIRAGLUTIDE COMPARED TO OTHER TYPE 2 DIABETES THERAPIES: META-ANALYSIS OF PHASE-3 STUDIES
42. FREQUENCY AND MAGNITUDE OF ANTIBODY FORMATION ARE LOWER WITH LIRAGLUTIDE THAN EXENATIDE: LEAD-6 RESULTS
43. CARDIOVASCULAR SAFETY OF LIRAGLUTIDE: A POOLED ANALYSIS FROM PHASE 2 AND 3 LIRAGLUTIDE CLINICAL DEVELOPMENT STUDIES
44. Complete remission of diabetes mellitus (type 1 or type 2)
45. Remission of diabetes mellitus (type 1 or type 2)
46. Partial remission of diabetes mellitus (type 1 or type 2)
47. Summary of the morphological and ecological traits of Central European dung beetles
48. Biodiversity conservation and protected areas in the Mediterranean region
49. Scope of the Problem: The Diabetes and Metabolic Syndrome Epidemic
50. The HEALTHY study: introduction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.